Eliem Therapeutics (ELYM) Competitors $1.95 -0.06 (-2.99%) As of 01/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ELYM vs. LFCR, HRTX, DSGN, ELDN, CMPS, FULC, SOPH, LRMR, ACB, and FDMTShould you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Lifecore Biomedical (LFCR), Heron Therapeutics (HRTX), Design Therapeutics (DSGN), Eledon Pharmaceuticals (ELDN), COMPASS Pathways (CMPS), Fulcrum Therapeutics (FULC), SOPHiA GENETICS (SOPH), Larimar Therapeutics (LRMR), Aurora Cannabis (ACB), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "pharmaceutical products" industry. Eliem Therapeutics vs. Lifecore Biomedical Heron Therapeutics Design Therapeutics Eledon Pharmaceuticals COMPASS Pathways Fulcrum Therapeutics SOPHiA GENETICS Larimar Therapeutics Aurora Cannabis 4D Molecular Therapeutics Lifecore Biomedical (NASDAQ:LFCR) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, community ranking, valuation, profitability, risk, earnings, dividends and media sentiment. Does the media favor LFCR or ELYM? In the previous week, Lifecore Biomedical had 4 more articles in the media than Eliem Therapeutics. MarketBeat recorded 4 mentions for Lifecore Biomedical and 0 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 1.19 beat Lifecore Biomedical's score of 0.65 indicating that Eliem Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Lifecore Biomedical Positive Eliem Therapeutics Positive Do insiders and institutionals believe in LFCR or ELYM? 83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 28.2% of Lifecore Biomedical shares are owned by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts rate LFCR or ELYM? Lifecore Biomedical presently has a consensus price target of $8.00, indicating a potential upside of 23.46%. Given Lifecore Biomedical's stronger consensus rating and higher probable upside, research analysts plainly believe Lifecore Biomedical is more favorable than Eliem Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifecore Biomedical 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, LFCR or ELYM? Lifecore Biomedical has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the S&P 500. Which has higher earnings and valuation, LFCR or ELYM? Lifecore Biomedical has higher revenue and earnings than Eliem Therapeutics. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Eliem Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifecore Biomedical$128.26M1.87$12.01M-$0.56-11.57Eliem TherapeuticsN/AN/A-$35.12M-$0.53-3.68 Is LFCR or ELYM more profitable? Eliem Therapeutics has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -12.52%. Eliem Therapeutics' return on equity of -47.03% beat Lifecore Biomedical's return on equity.Company Net Margins Return on Equity Return on Assets Lifecore Biomedical-12.52% -315.23% -12.74% Eliem Therapeutics N/A -47.03%-45.97% Does the MarketBeat Community believe in LFCR or ELYM? Eliem Therapeutics received 6 more outperform votes than Lifecore Biomedical when rated by MarketBeat users. Likewise, 56.25% of users gave Eliem Therapeutics an outperform vote while only 25.00% of users gave Lifecore Biomedical an outperform vote. CompanyUnderperformOutperformLifecore BiomedicalOutperform Votes325.00% Underperform Votes975.00% Eliem TherapeuticsOutperform Votes956.25% Underperform Votes743.75% SummaryLifecore Biomedical beats Eliem Therapeutics on 10 of the 16 factors compared between the two stocks. Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELYM vs. The Competition Export to ExcelMetricEliem TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$58.02M$6.21B$5.20B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E Ratio-3.689.2687.2517.09Price / SalesN/A309.921,263.9177.22Price / CashN/A61.4443.7736.04Price / Book0.506.055.314.79Net Income-$35.12M$154.90M$122.54M$224.99M7 Day Performance1.56%1.35%1.44%2.37%1 Month PerformanceN/A0.41%2.51%4.40%1 Year Performance-32.29%3.08%25.32%20.10% Eliem Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELYMEliem TherapeuticsN/A$1.95-3.0%N/A-32.3%$58.02MN/A-3.6820Positive NewsLFCRLifecore Biomedical1.6078 of 5 stars$6.36+1.1%$8.00+25.8%-7.8%$235.48M$130.86M79.50690Short Interest ↑HRTXHeron Therapeutics3.9388 of 5 stars$1.54-0.6%$5.67+268.0%-22.0%$234.23M$137.74M-8.56300Analyst UpgradePositive NewsDSGNDesign Therapeutics1.5937 of 5 stars$4.11-9.1%$7.00+70.3%+116.2%$232.71MN/A-4.8440Short Interest ↑News CoverageELDNEledon Pharmaceuticals2.2283 of 5 stars$3.89-3.7%$16.00+311.3%+140.7%$232.39MN/A-1.9410Positive NewsCMPSCOMPASS Pathways3.0395 of 5 stars$3.37-4.5%$33.60+897.0%-56.5%$230.58MN/A-1.53120Positive NewsFULCFulcrum Therapeutics2.0338 of 5 stars$4.17-4.6%$9.33+123.8%-42.8%$224.93M$80.87M-13.45100Positive NewsSOPHSOPHiA GENETICS2.96 of 5 stars$3.43+18.7%$7.40+115.7%-30.7%$224.24M$64.49M-3.15520News CoveragePositive NewsHigh Trading VolumeLRMRLarimar Therapeutics1.3894 of 5 stars$3.48-4.9%$20.43+487.0%-22.0%$222.05MN/A-3.0330Gap UpACBAurora Cannabis0.214 of 5 stars$4.03-2.4%N/A-6.4%$221.15M$296.99M-5.301,073Short Interest ↑FDMT4D Molecular Therapeutics3.4754 of 5 stars$4.76-13.8%$38.56+710.0%-73.1%$220.05M$17,000.00-1.67120Analyst Forecast Related Companies and Tools Related Companies Lifecore Biomedical Alternatives Heron Therapeutics Alternatives Design Therapeutics Alternatives Eledon Pharmaceuticals Alternatives COMPASS Pathways Alternatives Fulcrum Therapeutics Alternatives SOPHiA GENETICS Alternatives Larimar Therapeutics Alternatives Aurora Cannabis Alternatives 4D Molecular Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ELYM) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
